Holen Sie sich die Stockscreener-App
466.02
1.68%
-7.9767
Schlusskurs vom Vortag:
$474.00
Offen:
$477.66
24-Stunden-Volumen:
606.82K
Relative Volume:
0.52
Marktkapitalisierung:
$61.09B
Einnahmen:
$2.46B
Nettoeinkommen (Verlust:
$-319.09M
KGV:
-188.91
EPS:
-2.4669
Netto-Cashflow:
$-52.09M
1W Leistung:
-0.90%
1M Leistung:
+1.55%
6M Leistung:
+96.85%
1J Leistung:
+57.19%
1-Tages-Spanne:
$461.21
$480.53
1-Wochen-Bereich:
$461.21
$495.55
52-Wochen-Spanne:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Firmenname
Alnylam Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 551-8200
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Vergleichen Sie ALNY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
466.08 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.28 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.01 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.60 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
313.98 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-16 | Hochstufung | Goldman | Neutral → Buy |
| 2024-02-16 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-10-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-05-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-06-07 | Eingeleitet | William Blair | Outperform |
| 2022-04-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-01-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Hochstufung | Goldman | Neutral → Buy |
| 2021-11-22 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-08-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-02-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Fortgesetzt | Berenberg | Hold |
| 2020-09-08 | Eingeleitet | Citigroup | Buy |
| 2020-08-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-03-19 | Eingeleitet | Berenberg | Buy |
| 2019-12-19 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Bestätigt | Stifel | Buy |
| 2018-08-07 | Hochstufung | Stifel | Hold → Buy |
| 2018-05-04 | Bestätigt | Stifel | Hold |
| 2018-03-28 | Eingeleitet | Evercore ISI | In-line |
Alle ansehen
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.Earnings Overview Summary & Real-Time Chart Pattern Alerts - newser.com
What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Retail & Safe Capital Investment Plans - newser.com
Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Market Outlook & Daily Stock Momentum Reports - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikesInflation Watch & Long Hold Capital Preservation Plans - newser.com
Published on: 2025-10-21 18:00:20 - newser.com
Published on: 2025-10-21 15:17:29 - newser.com
Are Alnylam Shares Still Attractive After a 110% Surge and Fresh Pipeline News? - simplywall.st
Will Alnylam Pharmaceuticals Inc. (DUL) stock sustain bullish trend into 2025Trend Reversal & Risk Adjusted Buy/Sell Alerts - newser.com
Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryMarket Risk Report & Long-Term Growth Stock Strategies - newser.com
Is it time to cut losses on Alnylam Pharmaceuticals Inc.Weekly Profit Report & Community Verified Trade Signals - newser.com
How to recover losses in Alnylam Pharmaceuticals Inc. stockPortfolio Performance Summary & Weekly High Potential Stock Alerts - newser.com
Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratios2025 Volatility Report & Growth Focused Entry Point Reports - newser.com
Why Alnylam (ALNY) Might be Well Poised for a Surge - sharewise.com
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Navigating Growth Amidst a Potential -5.64% Downside - DirectorsTalk Interviews
News impact scoring models applied to Alnylam Pharmaceuticals Inc.2025 EndofYear Setup & AI Driven Stock Movement Reports - newser.com
A Fresh Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Strong Pipeline Momentum - simplywall.st
What drives Imagi International Holdings Limited BOI7 stock priceShort-Term Trading Alerts & Affordable Investment Strategies - earlytimes.in
Why Alnylam Pharmaceuticals Inc. stock is recommended by analysts2025 Trading Recap & Growth Focused Entry Reports - newser.com
Alnylam price target raised to $535 from $459 at Truist - Yahoo Finance
Is Alnylam Pharmaceuticals Inc. stock ready for breakout2025 Pullback Review & Safe Entry Momentum Stock Tips - nchmf.gov.vn
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growthJuly 2025 Patterns & Growth Oriented Trade Recommendations - nchmf.gov.vn
What to do if you’re stuck in Alnylam Pharmaceuticals Inc.2025 EndofYear Setup & Verified Trade Idea Suggestions - newser.com
Truist Securities Raises Price Target for Alnylam Pharmaceuticals (ALNY) by 16.56% | ALNY Stock News - GuruFocus
Alnylam stock price target raised to $535 from $459 by Truist Securities - Investing.com
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results - BioSpace
Alnylam Pharmaceuticals Hits New 52-Week High of $485.28 - Markets Mojo
Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following New Partnerships, Pipeline Progress, and Fresh Financing - Yahoo Finance
Responsive Playbooks and the ALNY Inflection - news.stocktradersdaily.com
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - sharewise.com
Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD By Investing.com - Investing.com Nigeria
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice - Yahoo Finance
Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD - Investing.com
What Catalysts Are Shaping the Evolving Narrative for Alnylam Pharmaceuticals? - Yahoo Finance
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Phase 3 ZENITH Study Launch for Zilebesiran - simplywall.st
Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
0.43%
2.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):